HDE supplement
H170002 S015: LIPOSORBER® LA-15 System
FDA HDE supplement · 30-day notice · Kaneka Pharma America LLC
Key facts
| Original HDE | H170002 |
|---|---|
| Supplement number | S015 |
| Supplement type | 30-day notice |
| Reason for the supplement | process change - manufacturer/sterilizer/packager/supplier |
| Trade name | LIPOSORBER® LA-15 System |
| Generic name | Apheresis for focal glomerulosclerosis in adult and pediatric patients |
| Applicant | Kaneka Pharma America LLC |
| Product code | PBN |
| Received date | Jul 29, 2024 |
| Decision date | Aug 27, 2024 |
At a glance
- No Approval order on file
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About HDE supplements
An HDE supplement asks FDA to approve a change to a Humanitarian Use Device that already holds a humanitarian device exemption.
Source: U.S. Food and Drug Administration (FDA), Humanitarian Device Exemption (HDE) database · Source date: